相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Nico Gagelmann et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
Lisa Pleyer et al.
LANCET HAEMATOLOGY (2021)
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia
Allan Beke et al.
HAEMATOLOGICA (2020)
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management
Peter Valent
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients
Giacomo Coltro et al.
LEUKEMIA (2020)
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero et al.
BLOOD (2020)
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
BLOOD (2020)
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Lionel Ades et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Kiyomi Morita et al.
BLOOD (2020)
Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
Raphael Itzykson et al.
BLOOD (2020)
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
Abhishek A. Mangaonkar et al.
BLOOD ADVANCES (2020)
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Michael R. Savona et al.
BLOOD (2020)
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML
Sandrine Niyongere et al.
LEUKEMIA (2019)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas et al.
LEUKEMIA (2019)
Update on the pathologic diagnosis of chronic myelomonocytic leukemia
Daniel A. Arber et al.
MODERN PATHOLOGY (2019)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona et al.
LANCET HAEMATOLOGY (2019)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guillermo Garcia-Manero et al.
LANCET HAEMATOLOGY (2019)
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Anthony M. Hunter et al.
BLOOD (2019)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
Sophie Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Guillermo Garcia-Manero et al.
BLOOD (2019)
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
David P. Steensma et al.
BLOOD (2019)
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
V. Santini et al.
LEUKEMIA (2018)
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1
Sonja Burgstaller et al.
LEUKEMIA & LYMPHOMA (2018)
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations
Hatice D. Gur et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia
Maliha Khan et al.
ANNALS OF HEMATOLOGY (2018)
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone
Mrinal M. Patnaik et al.
LEUKEMIA (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
Mrinal M. Patnaik et al.
BLOOD CANCER JOURNAL (2018)
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia
Anthony M. Hunter et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis
Aaron T. Gerds et al.
BLOOD (2018)
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero et al.
BLOOD (2018)
Leukocytosis Is Associated with End Organ Damage in Chronic Myelomonocytic Leukemia (CMML) and Can be Mitigated with Cytoreductive Therapy
Anthony Hunter et al.
BLOOD (2018)
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
Sanam Loghavi et al.
BLOOD ADVANCES (2018)
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia
Mohammad Faizan Zahid et al.
LEUKEMIA & LYMPHOMA (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
Julia T. Geyer et al.
MODERN PATHOLOGY (2017)
Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression
Kseniya Petrova-Drus et al.
ONCOTARGET (2017)
Hypomethylating Agent Therapy Use and Survival in Older Patients With Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Amer M. Zeidan et al.
CANCER (2017)
Monocytosis in polycythemia vera: Clinical and molecular correlates
Daniela Barraco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia
Blanca Xicoy et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia
Markus Ball et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia
Eric Solary
CLINICAL CANCER RESEARCH (2016)
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron et al.
CLINICAL CANCER RESEARCH (2016)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede et al.
NATURE COMMUNICATIONS (2016)
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2016)
Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
Dorothee Selimoglu-Buet et al.
BLOOD (2015)
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Argiris Symeonidis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes
Jennifer Schemenau et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
Guilin Tang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
Emnet A. Wassie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia
M. W. Drummond et al.
LEUKEMIA (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
E. Schuler et al.
LEUKEMIA RESEARCH (2014)
Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
Lisa Pleyer et al.
LEUKEMIA RESEARCH (2014)
Chronic Myelomonocytic Leukemia Monocytes Uniformly Display a Population of Monocytes With CD11c Underexpression
Payal Sojitra et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron et al.
BLOOD (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Clonal architecture of chronic myelomonocytic leukemias
Raphael Itzykson et al.
BLOOD (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
M. M. Patnaik et al.
LEUKEMIA (2013)
Treatment of chronic myelomonocytic leukemia with azacitidine
Eric Wong et al.
LEUKEMIA & LYMPHOMA (2013)
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study
Luana Fianchi et al.
LEUKEMIA & LYMPHOMA (2013)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
Lionel Ades et al.
LEUKEMIA RESEARCH (2013)
Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727
Aram Oganesian et al.
BLOOD (2013)
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
Donald Lavelle et al.
BLOOD (2012)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Manja Meggendorfer et al.
BLOOD (2012)
The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias
Marian A. Rollins-Raval et al.
HISTOPATHOLOGY (2012)
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
Michael Thorpe et al.
LEUKEMIA RESEARCH (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities
Hesham Eissa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska et al.
BLOOD (2011)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Activity of Azacitidine in Chronic Myelomonocytic Leukemia
Rubens Costa et al.
CANCER (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2011)
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Ronan T. Swords et al.
BLOOD (2010)
Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
P. Krishnamurthy et al.
BONE MARROW TRANSPLANTATION (2010)
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
Clara Ricci et al.
CLINICAL CANCER RESEARCH (2010)
S110, a 5-Aza-2′-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth
Jody C. Chuang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
James E. Brownell et al.
MOLECULAR CELL (2010)
Morphological evaluation of monocytes and their precursors
Jean E. Goasguen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation
M-C Kuo et al.
LEUKEMIA (2009)
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
Veronique Gelsi-Boyer et al.
BMC CANCER (2008)
A pilot pharmacokinetic study of oral azacitidine
G. Garcia-Manero et al.
LEUKEMIA (2008)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
A multicenter phase 2 study of the famesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Pierre Fenaux et al.
BLOOD (2007)
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome - Comparison with historical experience
Hagop M. Kantarjian et al.
CANCER (2007)
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
M Elliott et al.
BONE MARROW TRANSPLANTATION (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system
T Chiba et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2004)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia.: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Expression and prognostic significance of Bcl-2 family proteins in Myelodysplastic syndromes
D Boudard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic evaluation of the microvascular network in myelodysplastic syndromes
P Korkolopoulou et al.
LEUKEMIA (2001)
分享论文
